Bildkälla: Stockfoto

Active Biotech: Interim Phase Ib Results from NeoTX - Redeye

NeoTX, the partner of Active Biotech developing naptumomab estafenatox, has presented new results from the phase I/IIa trial combining naptumomab with durvalumab at the AACR Annual Meeting 2023.

NeoTX, the partner of Active Biotech developing naptumomab estafenatox, has presented new results from the phase I/IIa trial combining naptumomab with durvalumab at the AACR Annual Meeting 2023.
Börsvärldens nyhetsbrev
ANNONSER